A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.

Phase 1

IDEAYA Biosciences